Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated April 17, 2025, serves as a transaction notification for Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. The report details share acquisitions executed on April 15 and April 16, 2025, on the London Stock Exchange (XLON) and New York Stock Exchange (XNYS).
Key Financial Metrics and Transaction Details
The filing does not contain company-wide financial metrics such as revenue, profit, cash flow, or debt levels. It exclusively reports on specific insider transactions involving the re-investment of dividends paid on April 10, 2025.
| Instrument | Transaction Type | Price | Total Volume | Exchange |
|---|---|---|---|---|
| Ordinary Shares (GBP) | Deferred Annual Bonus Plan Re-investment | £12.7500 | 15,556 shares | XLON |
| Ordinary Shares (GBP) | Performance Share Plan Re-investment | £12.7500 | 11,184.93 shares | XLON |
| American Depositary Shares (USD) | Dividend Re-investment | $33.6000 - $35.9948 | 4,766.175 ADSs | XNYS |
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy. The only changes reported are increases in the notional interest or acquisition of shares by specific executives and directors as part of standard compensation plans.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of insider trading activity compliant with Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions are automatic re-investments of dividends into the company's Deferred Annual Bonus Plan or Performance Share Plan; no open-market purchases or sales were made by the executives.
- Share Price: Ordinary shares traded at £12.7500 on April 16, 2025. ADS prices ranged from $33.6000 to $35.9948 on April 15-16, 2025.
- Participants: Transactions involved 13 senior executives and directors, including CEO Emma Walmsley, CFO Julie Brown, and Non-Executive Director Dr. Hal Barron.
- Dividend Date: The underlying dividends were paid to shareholders on April 10, 2025.